⬆️prevalence of HCQ retinopathy: Kaiser Permanente 676 pts retrospect study #OP0133 👉6.8% (n=46) had HCQ retinopathy w/ risks: 👉age>80 (OR 3.83) 👉h/o atherosclerosis (OR 2.99), 👉cum. dose >2000 mg (OR 15.8) 👉10-15 yrs use (OR 4.44) 👉>15 yrs (OR 19) #EULAR2021 @rheumnow https://t.co/QA8HHXdnjL

Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow

Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of GC's+HCQ? @rheumnow @kidneydoc101 @Lupusreference

The case for starting combo Rx for LN (rather than sequential Rx): 👉Aurora trial: voclosporin + MMF (vs. MMF only) prompt efficacy on proteinuria across all ethnic subgroups, twice more complete renal response , no major safety signals. slide 1/ #EULAR2021 @rheumnow https://t.co/TA5i9ITuL7

OP0131: Pooled data from TULIP-1 and TULIP-2 show anifrolumab (anti-IFN receptor Ab) show improvement of rash and arthritis. Shows promise for drug, particularly in subset of pts with high IFN activity #EULAR2021 @RheumNow https://t.co/sddF2NRlEg

Can we taper IV belimumab in #SLE? Dr Fredi reported 14/48 (29%) extended tx to at least 5-weekly after 12mo of tx. No worsening C3/C4 & PGA but interestingly #steroid and SLEDAI ⬇️. More works needed to identify suitable pts for taper and regime #EULAR2021 #POS0107 @RheumNow https://t.co/Gwe7mPWPdY

In a UK 🇬🇧 study of newly diagnosed #SLE, Dr Yee reported higher damage in the first 3yrs but then stabilised. Death rate in the first 12yrs had improved to 4.8% (mostly heart disease and infection) but could still occur early (within 5yr diagnosis) #EULAR2021 #POS0111 @RheumNow

In patients with #SLE who attained LLDAS, a retrospective cohort study by Dr Cunha identified predictors of flares including anti-RNP +ve, concomitant immunosuppressant and oral prednisolone. Important to account these during follow-up #EULAR2021 #POS0105 @RheumNow

🚨So after LoVAS Now this Ritux + MMF + Pulse MPS No oral steroids 🤯 @ARD_BMJ @EBRheum - Lesser is better ?? https://t.co/CYMNX8wLtd https://t.co/NtwTas3ZdS

• https://ard.bmj.com/content/72/8/1280.long